Concepedia

Author

Peter Köhler

University of Wisconsin–MadisonORCID

Also Known As

KOHLER P., Kohler, Peter, Köhler, Peter, Köhler, Peter, P C Kohler, P Köhler, P. C. Kohler, P. Kohler, P. Köhler, PETER KOHLER

113

Publications

1.6K

Citations

22

H-Index

72

Concepts

All Affiliations

University of Wisconsin–MadisonKarolinska University HospitalMeriter HospitalWilliam S. Middleton Memorial Veterans HospitalMunson Medical Center
PK

About

Peter Köhler is an author at University of Wisconsin–Madison specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

20

859

2

Health Sciences

4

4

317

3

Allergy

4

4

299

4

Engineering

2

2

34

5

Public Health

1

1

15

Peter Köhler

×

33

Publications

1.4K

Citations

22

H-Index

YearCitations

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

Paul M. Sondel, Peter Köhler, J A Hank,

PubMed

1988

158

Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1

Jeffrey A. Sosman, Peter Köhler, Jacquelyn A. Hank,

JNCI Journal of the National Cancer Institute

1988

137

Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.

Paul M. Sondel, Jacquelyn A. Hank, Peter Köhler,

The Journal of Immunology

1986

115

Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment

Fernando Dimeo, Alexander Schmittel, Thomas Fietz,

Annals of Oncology

2004

113

Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin

Jeff Sosman, Peter Köhler, J A Hank,

JNCI Journal of the National Cancer Institute

1988

109

Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.

R. R. Brown, C M Lee, Peter Köhler,

PubMed

1989

81

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

J A Hank, Peter Köhler, G Weil-Hillman,

PubMed

1988

81

Physical properties of autoclaved bone: Torsion test of rabbit diaphyseal bone

Peter Köhler, Andris Kreicbergs, Lennart Strömberg

Acta Orthopaedica Scandinavica

1986

53

Phase II Trial of Oral Altretamine for Consolidation of Clinical Complete Remission in Women with Stage III Epithelial Ovarian Cancer: A Southwest Oncology Group Trial (SWOG-9326)

Mace L. Rothenberg, P.Y. Liu, Sharon P. Wilczynski,

Gynecologic Oncology

2001

34

Phase I study of toremifene in patients with advanced cancer.

John Hamm, D C Tormey, Peter Köhler,

Journal of Clinical Oncology

1991

34

Page 1